Radient Pharmaceuticals Corporation (RXPC) issued corporate report today, July 13th, 2011. It highlights investment catalysts in 5 key areas of Radient’s business. These catalysts include the Company’s: •Recent Focus on IVD Business •Multiple Revenue Stream Opportunities •Building Marketing & Distribution Channels for Approved Indications •Plan To Introduce IVDs for New Indications in US In Conjunction […]